Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate | Zendy

E. Linden-Castro | Zendy; M. Pelayo-Nieto | Zendy; Alejandro Alías-Melgar | Zendy; D. Espinosa-Perezgrovas | Zendy; I.A. Ramírez-Galindo | Zendy; Gabriel Catalán-Quinto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate

Author(s) -

E. Linden-Castro,

M. Pelayo-Nieto,

Alejandro Alías-Melgar,

D. Espinosa-Perezgrovas,

I.A. Ramírez-Galindo,

Gabriel Catalán-Quinto

Publication year - 2014

Publication title -

case reports in urology

Language(s) - English

Resource type - Journals

eISSN - 2090-696X

pISSN - 2090-6978

DOI - 10.1155/2014/508305

Subject(s) - abiraterone acetate , prostate cancer , medicine , prostate , prostate adenocarcinoma , urology , adenocarcinoma , prostatic adenocarcinoma , oncology , cancer , androgen deprivation therapy

Ductal adenocarcinoma of the prostate is a rare histological variant that only represents <1% of prostate tumors. This histological variant has several important clinical implications with respect to their evolution, clinical prognosis, and treatment. We report the case of a 64-year-old patient with ductal adenocarcinoma of the prostate, which progresses to castration-resistant prostate cancer, that was treated with abiraterone acetate with good clinical response, to our knowledge, the first case of ductal adenocarcinoma of the prostate in treatment with abiraterone acetate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research